# ToBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tobio

- Industry: Biotechnology
- Headquarters: Wuhan, China
- Total disclosed funding: $6.8M
- Latest round: Angel (Jan 11, 2025)
- Investors on record: 2

## About

Based in Wuhan, China, and founded in 2024, ToBio, Inc is a molecular diagnostics company. It has R&D centers in Boston and Shanghai. In January 2025, ToBio, Inc raised CNY 50 million in angel funding led by new investor Rivercity Investment, with participation from other new investor Kindstar Globalgene Technology, Inc.

The company mainly provides diagnostic technology platforms and molecular companion diagnostic (POCT) technologies. Its polymerase chain reaction (PCR) detection equipment can complete the detection of thousands of targets within 15 to 30 minutes and issue a report.

The company generates revenue by developing diagnostic technology platforms and molecular companion diagnostics (POCT) technologies.

The company will use the funds for technology transformation, product development and global market expansion of medical devices.

## Funding rounds

- Angel, Jan 11, 2025, $6.8M — Kindstar Globalgene Technology, Inc., Rivercity Investment

## Investors

- Kindstar Globalgene Technology, Inc. — Angel
- Rivercity Investment (https://capitalatlas.ai/funds/rivercity-investment) — Angel